News und Analysen
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Evercore ISI HealthCONx
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Evercore ISI HealthCONx
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Evercore ISI HealthCONx
![Humana and agilon health Expand Relationship, Announce Value-Based Agreements with Physician Groups](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Humana and agilon health Expand Relationship, Announce Value-Based Agreements with Physician Groups
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, announced today that it has signed value-based care agreements with agilon health, which helps physicians and
![Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology
![LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will
![LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen der Medizintechnik und Innovation, gab heute bekannt, dass es sein Programm Caisson Transcatheter Mitral Valve Replacement (TMVR) beendet
![Heat Biologics: Aktie explodiert - darauf ist jetzt zu achten!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Heat Biologics: Aktie explodiert - darauf ist jetzt zu achten!
Der Aktienkurs von Heat Biologics (WKN: A2JB4Y) erlebt derzeit ein wahres Auf und Ab. Wohin die Reise letztendlich geht, entscheiden die jetzt veröffentlichten Topline-Daten zur
![Prothena: NBC-Bonusaktie marschiert +60% in 5 Wochen](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Prothena: NBC-Bonusaktie marschiert +60% in 5 Wochen
Am 29. August stellten wir NBC-Mitgliedern die irische Prothena (WKN: A1KAVV) als Bonusaktie vor. Zu diesem Zeitpunkt hatte die Value-Perle unsere gewünschte Kaufzone bis 7,50 USD bereits
![Humana and Hawaii Senior Medical Group Announce Agreement Expanding Value-Based Care for Humana Medicare Advantage Members in Hawaii](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Humana and Hawaii Senior Medical Group Announce Agreement Expanding Value-Based Care for Humana Medicare Advantage Members in Hawaii
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced it has collaborated with Hawaii Senior Medical Group on a value-based agreement designed to offer a coordinated
![Humana Pharmacy Wins Specialty Pharmacy Patient Choice Award, Two Years in a Row](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Humana Pharmacy Wins Specialty Pharmacy Patient Choice Award, Two Years in a Row
The specialty pharmacy team of Humana Pharmacy, the mail-delivery pharmacy service of Humana Inc. (NYSE: HUM), received the Specialty Pharmacy Patient Choice Award in the PBM/Payer Specialty
![LivaNova to Present at the Berenberg and Piper Jaffray Conferences](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova to Present at the Berenberg and Piper Jaffray Conferences
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference
![Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence
Agilent Technologies Inc. (NYSE: A) today announced a new generation of ICP-OES systems for laboratories serving the environmental, food, energy, chemicals, and materials markets.
The new Agilent
![Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted
![Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at
![Qiagen: Kommt es jetzt doch zu einem Bieterkampf?](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Qiagen: Kommt es jetzt doch zu einem Bieterkampf?
Erst vor wenigen Tagen berichtete ich an dieser Stelle hier auf sharedeals.de über aufkeimende Übernahmespekulationen bei Qiagen (WKN: A2DKCH).
Angeblich, so hatte der US-Finanznachrichtendienst
![Qiagen: Kommt es jetzt doch zu einem Bieterkampf?](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Qiagen: Kommt es jetzt doch zu einem Bieterkampf?
Erst vor wenigen Tagen berichtete ich an dieser Stelle hier auf sharedeals.de über aufkeimende Übernahmespekulationen bei Qiagen (WKN: A2DKCH).
Angeblich, so hatte der US-Finanznachrichtendienst
![MorphoSys: Blutkrebsmedikament scheint auf sehr gutem Weg](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
MorphoSys: Blutkrebsmedikament scheint auf sehr gutem Weg
Wie das deutsche Biotechunternehmen MorphoSys (WKN: 663200) heute Nachmittag bekanntgab, verlaufen die klinischen Studien mit seinem Blutkrebsmedikament MOR208 (Tafasitamab) wohl sehr gut.
So hat
![MorphoSys: Blutkrebsmedikament scheint auf sehr gutem Weg](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
MorphoSys: Blutkrebsmedikament scheint auf sehr gutem Weg
Wie das deutsche Biotechunternehmen MorphoSys (WKN: 663200) heute Nachmittag bekanntgab, verlaufen die klinischen Studien mit seinem Blutkrebsmedikament MOR208 (Tafasitamab) wohl sehr gut.
So hat
![The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies
![Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Badrul Chowdhury, M.D., Ph.D., to the newly created position of Chief Medical Officer (CMO), effective
![FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the
![FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the
![The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical
![QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional